Navigation Links
YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
Date:8/10/2009

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revis
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Second Quarter 2009 Results
3. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
4. SAFC Biosciences(R) Defines Hydrolysate Components That Enhance Chinese Hamster Ovary (CHO) Cell Line Protein Production
5. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
7. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
8. Regado Biosciences Expands Medical Advisory Board
9. YM BIOSCIENCES SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG
10. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
11. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 1 Iomai Corporation,(Nasdaq: IOMI ) ... merger of,Iomai with a wholly-owned subsidiary of ... shares entitled to vote at the special,meeting ... of the,votes cast. The transaction remains subject ...
... MS, EDMONTON, Aug. 1 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that it ... trial of MBP8298 (dirucotide) for the treatment of ... approximately,510 patients, and is being conducted at 68 ...
... Associates has announced the development of the Core Communications Program, ... investors, collaborators, and customers. , ... ... http://www.mainsgate.com [Mains Associates] has announced the availability of ...
Cached Biology Technology:BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 2BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 3BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 4Bay-Area Company Gives Science-Based Startups a Voice 2
(Date:7/9/2014)... the bladders of healthy women differ from bacteria ... according to researchers from Loyola University Chicago Stritch ... July 9, 2014, in the American Society for ... bacterial communities may play a role in female ... a common, yet poorly understood, condition with symptoms ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2Not at home on the range 2Not at home on the range 3Not at home on the range 4
... COLUMBUS, Ohio Ohio State University cancer researchers ... brain-tumor cells and blocks the growth of new tumor ... to kill cancer cells oncolytic viruses might ... also carry a gene for a protein that inhibits ...
... NEW YORK, Dec. 1 iQor, a global provider of business ... 100 Awards Top 100 IT project of 2009 for its ... , "We are honored to be recognized among this prestigious list ... is completely transforming the way we do business, allowing us to ...
... bad cold, can spread among groups of people, research ... Diego and Harvard shows. Using longitudinal data from a ... more than 60 years, a team of scholars found ... others. Gradually over time, a group of lonely, disconnected ...
Cached Biology News:Tumor-attacking virus strikes with 'one-two punch' 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Loneliness can be contagious 2Loneliness can be contagious 3
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
Biology Products: